IP Library Granted Patent US 9,499,630
Granted Patent B2
US 9,499,630 · App. 13/974,792 · Granted Nov 22, 2016

Frizzled-binding agents and uses thereof

Inventor: Austin L. Gurney (San Francisco, CA)
Assignee: OncoMed Pharmaceuticals, Inc.
C07K16/30C07K14/4702C07K14/71C07K16/28C07K2317/34C07K2317/55C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,630
App. No.
13/974,792
Granted
Nov 22, 2016
Kind
B2
Abstract

Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.

Claims (25)

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:98-116, wherein the amino acid sequence specifically binds a human Frizzled (FZD) receptor.

2. The polypeptide of claim 1 ,

(a) which is less than 100 amino acids in length;

(b) which is less than 20 amino acids in length;

(c) which has a molecular weight of less than 2000 Daltons;

(d) which is a modified polypeptide;

(e) which is detectably labeled;

(f) which is a cyclic polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:98-112;

(g) which is a linear polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID Nos:113-116; and/or

(h) which is an inhibitor of Wnt signaling.

3. The polypeptide of claim 1 , which consists of an amino acid sequence selected from the group consisting of SEQ ID NO:98-116.

4. The polypeptide of claim 1 , which comprises the amino acid sequence of SEQ ID NO:112.

5. The polypeptide of claim 1 , which comprises the amino acid sequence of SEQ ID NO:108.

6. The polypeptide of claim 1 , wherein the human FZD receptor is FZD8.

7. The polypeptide of claim 1 , wherein

(a) the polypeptide inhibits the binding of a Wnt to a human FZD receptor; or

(b) the polypeptide inhibits the binding of Wnt3A to the human FZD8 receptor.

8. The polypeptide of claim 1 , wherein the polypeptide inhibits Wnt signaling.

9. A pharmaceutical composition comprising the polypeptide of claim 1 .

10. An inhibitor of Wnt signaling which comprises the polypeptide of claim 1 .

11. A method of inhibiting Wnt signaling in a cell, comprising contacting the cell with an effective amount of the polypeptide of claim 1 .

12. The method of claim 11 , wherein the cell is a tumor cell.

13. A method of inducing differentiation of a cell, comprising contacting the cell with an effective amount of the polypeptide of claim 1 .

14. The method of claim 13 , wherein the cell is a tumor cell.

15. A method of inhibiting growth of a tumor, comprising contacting the tumor with an effective amount of the polypeptide of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Oct 23, 2020
From: ONCOMED PHARMACEUTICALS, INC.
To: MEREO BIOPHARMA 5, INC.
Reel/Frame 054193/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2013
From: GURNEY, AUSTIN L.
To: ONCOMED PHARMACEUTICALS, INC.
Reel/Frame 031674/0497 →
Continuity (3)
Division 13078728 · Apr 1, 2011
Provisional Application 61320175 · Apr 1, 2010
Related Publication 20140105917A1 · Apr 17, 2014